225 related articles for article (PubMed ID: 1983054)
21. Vasodilatory action of carvedilol.
Sponer G; Strein K; Bartsch W; Müller-Beckmann B
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
[TBL] [Abstract][Full Text] [Related]
22. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
Sanderson JE; Chan WW; Hung YT; Chan SK; Shum IO; Raymond K; Woo KS
Br Heart J; 1995 Nov; 74(5):502-7. PubMed ID: 8562234
[TBL] [Abstract][Full Text] [Related]
23. A rest and exercise haemodynamic evaluation of a new cardio-selective beta-adrenoceptor blocker celiprolol alone and in combination with nitroglycerine in ischaemic heart disease.
Silke B; Verma SP; Frais MA; Reynolds G; Taylor SH
Br J Clin Pharmacol; 1986 Dec; 22(6):697-706. PubMed ID: 2882772
[TBL] [Abstract][Full Text] [Related]
24. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease.
Lahiri A; Rodrigues EA; DasGupta P; Jain D; van der Does R; Raftery EB
Z Kardiol; 1989; 78 Suppl 3():21-7. PubMed ID: 2573213
[TBL] [Abstract][Full Text] [Related]
25. Sympathetic activation and the role of beta-blockers in chronic heart failure.
Krum H
Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514
[TBL] [Abstract][Full Text] [Related]
26. Vasodilating beta-blockers in heart failure.
Raftery EB
Eur Heart J; 1995 Jul; 16 Suppl F():32-7. PubMed ID: 8521882
[TBL] [Abstract][Full Text] [Related]
27. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
McTavish D; Campoli-Richards D; Sorkin EM
Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
[TBL] [Abstract][Full Text] [Related]
28. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
[TBL] [Abstract][Full Text] [Related]
29. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
[TBL] [Abstract][Full Text] [Related]
30. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
Brittain RT; Levy GP
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
[TBL] [Abstract][Full Text] [Related]
31. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
32. The vasodilatory beta-blockers.
Pedersen ME; Cockcroft JR
Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
[TBL] [Abstract][Full Text] [Related]
33. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H
Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575
[TBL] [Abstract][Full Text] [Related]
34. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
[TBL] [Abstract][Full Text] [Related]
35. Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.
Lund-Johansen P; Omvik P
Cardiovasc Drugs Ther; 1991 Jun; 5(3):605-15. PubMed ID: 1678963
[TBL] [Abstract][Full Text] [Related]
36. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers.
De Cree J; Van Nueten L; Geukens H; Verhaegen H
Int J Clin Pharmacol Res; 1992; 12(4):159-63. PubMed ID: 1363660
[TBL] [Abstract][Full Text] [Related]
37. Haemodynamic effects of new beta-blockers with vasodilatory properties in essential hypertension.
Tsukiyama H; Otsuka K; Horii M
Drugs; 1988; 36 Suppl 6():48-54. PubMed ID: 2908304
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.
Lund-Johansen P
J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S12-7. PubMed ID: 2464093
[TBL] [Abstract][Full Text] [Related]
39. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.
van Zwieten PA
Drugs; 1993 Apr; 45(4):509-17. PubMed ID: 7684671
[TBL] [Abstract][Full Text] [Related]
40. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.
Bril A; Slivjak M; DiMartino MJ; Feuerstein GZ; Linee P; Poyser RH; Ruffolo RR; Smith EF
Cardiovasc Res; 1992 May; 26(5):518-25. PubMed ID: 1359930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]